Alnylam (ALNY) Tops Q4 EPS by 28c but Revenue Falls Short, Offers Guidance
Tweet Send to a Friend
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q4 EPS of ($1.20), $0.28 better than the analyst estimate of ($1.48). Revenue for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
